First published 10/3/2026, 12:36:15 AM · Last updated 10/3/2026, 12:36:15 AM

EP.01.16 Differential Effect of Neoadjuvant Therapy in Locally Advanced Non-Small Cell Lung Cancer Based on Sex

A journal article published by Elsevier BV on 2025-10-01 addressing differences by sex in neoadjuvant therapy for locally advanced non-small cell lung cancer. The source provided only bibliographic metadata and the article title without additional study details.

Illustrative image: Patients median survival with Atezolizumab (Atezo) for treatment of non small cell lung cancer in the first line, IMpower 110 comparing Atezo to chemotherapy , IMpower 130 comparing Atezo+chemotherapy to chemotherapy and IMpower150 comparing ATEZOLIZUMAB+ chemotherapy + bevacizumab versus chemotherapy + bevacizumab — Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 1/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The topic relates to clinical and research understanding of cancer treatment differences by sex, but the source gave no outcome or data.

Sources

EP.01.16 Differential Effect of Neoadjuvant Therapy in Locally Advanced Non-Small Cell Lung Cancer Based on Sex

Report an issue